Hundreds of homes approved despite job concerns
Plans to build more than 250 homes and an 80-bedroom care home in Stamford will go ahead, despite concerns about the "long-term sustainability" of the town.
The Exeter Fields development, for agricultural land off Empingham Road, was approved by South Kesteven District Council (SKDC) at a meeting on Thursday.
Town councillor Barry Devereux was among opponents who argued the site should be retained for employment use, because more housing without job opportunities would threaten the viability of the town.
But Andrew McPheat, from applicant Commercial Estates Group said there was no "appetite or demand" to justify "a strategic employment site".
The plans cover a 22-acre site between a Taylor Wimpey housing estate and the A1, the Local Democracy Reporting Service said.
Of the 268 homes, 80 would be "affordable" and there would be a local centre with shops and community buildings.
However, in 2012, Exeter Fields was set aside for industrial and commercial use. During the meeting, residents and councillors argued it should remain reserved for employment, noting Stamford's growing population.
Councillor Richard Cleaver, the cabinet member for property at SKDC, said the site was "completely irreplaceable" and allowing the application would deprive the town "of any employment opportunities within its boundaries forever".
The idea that a site so close to the A1 was unsuitable for employment was "frankly laughable", he added.
Mr McPheat said the landowners had spent 10 years marketing the site to potential occupiers, but had found no demand for it as an employment site.
He argued a local centre in the estate could create up to 155 direct and 78 indirect jobs.
Council planning officers acknowledged the concerns but warned that if developers were "not willing to develop" then the land could not be retained "indefinitely".
Councillor Helen Crawford backed the application, noting that "employment has changed", particularly since the Covid-19 pandemic, with more people now working from home.
In total, nine committee members voted to approve the development while two voted against.
The proposal was put forward by Commercial Estates Group and the Cecil Estate Family Trust.
Listen to highlights from Lincolnshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
New homes approved despite concerns for village
Council hopes not to lose money on land deal
'Significant milestone' reached at derelict site
South Kesteven District Council
Commercial Estates Group
Local Democracy Reporting Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Darden (NYSE:DRI) Reports Q2 In Line With Expectations
Restaurant company Darden (NYSE:DRI) met Wall Street's revenue expectations in Q2 CY2025, with sales up 10.6% year on year to $3.27 billion. Its GAAP profit of $2.58 per share was 12.1% below analysts' consensus estimates. Is now the time to buy Darden? Find out in our full research report. Revenue: $3.27 billion vs analyst estimates of $3.26 billion (10.6% year-on-year growth, in line) EPS (GAAP): $2.58 vs analyst expectations of $2.94 (12.1% miss) EPS (GAAP) guidance for the upcoming financial year 2026 is $10.60 at the midpoint, missing analyst estimates by 1.2% Operating Margin: 11.7%, down from 13.4% in the same quarter last year Free Cash Flow Margin: 8.4%, down from 9.7% in the same quarter last year Locations: 2,159 at quarter end, up from 2,031 in the same quarter last year Same-Store Sales rose 4.6% year on year (0% in the same quarter last year) Market Capitalization: $26.07 billion "We had a strong quarter with same-restaurant sales and earnings growth that exceeded our expectations," said Darden President & CEO Rick Cardenas. Founded in 1968 as Red Lobster, Darden (NYSE:DRI) is a leading American restaurant company that owns and operates a portfolio of popular restaurant brands. Examining a company's long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. With $12.08 billion in revenue over the past 12 months, Darden is one of the most widely recognized restaurant chains and benefits from customer loyalty, a luxury many don't have. Its scale also gives it negotiating leverage with suppliers, enabling it to source its ingredients at a lower cost. However, its scale is a double-edged sword because there is only so much real estate to build restaurants, placing a ceiling on its growth. For Darden to boost its sales, it likely needs to adjust its prices, launch new chains, or lean into foreign markets. As you can see below, Darden's sales grew at a mediocre 6% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts) as it barely increased sales at existing, established dining locations. This quarter, Darden's year-on-year revenue growth was 10.6%, and its $3.27 billion of revenue was in line with Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 8.7% over the next 12 months, an acceleration versus the last six years. This projection is above average for the sector and indicates its newer menu offerings will catalyze better top-line performance. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Darden sported 2,159 locations in the latest quarter. Over the last two years, it has opened new restaurants at a rapid clip by averaging 6.1% annual growth, among the fastest in the restaurant sector. When a chain opens new restaurants, it usually means it's investing for growth because there's healthy demand for its meals and there are markets where its concepts have few or no locations. The change in a company's restaurant base only tells one side of the story. The other is the performance of its existing locations, which informs management teams whether they should expand or downsize their physical footprints. Same-store sales is an industry measure of whether revenue is growing at those existing restaurants and is driven by customer visits (often called traffic) and the average spending per customer (ticket). Darden's demand within its existing dining locations has been relatively stable over the last two years but was below most restaurant chains. On average, the company's same-store sales have grown by 1.7% per year. This performance suggests it should consider improving its foot traffic and efficiency before expanding its restaurant base. In the latest quarter, Darden's same-store sales rose 4.6% year on year. This growth was an acceleration from its historical levels, which is always an encouraging sign. We enjoyed seeing Darden beat analysts' same-store sales expectations this quarter. We were also happy its revenue was in line with Wall Street's estimates. On the other hand, its EPS fell short of Wall Street's estimates. Looking ahead, EPS guidance also came in below expectations. Overall, this was a weaker quarter. The stock remained flat at $221 immediately following the results. Darden didn't show it's best hand this quarter, but does that create an opportunity to buy the stock right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Stock picks and perspectives from a mutual fund approaching its hundredth anniversary
Since its 1934 launch, Capital Group's $200 billion–plus Investment Company of America fund has rolled with the changes. From a manufacturing-based post–World War II economy to a services one in the 1980s, and from the old economy to the new one, the fund 'has evolved alongside the U.S. economic landscape,' Anita Patel, an investment director and public face of the strategy that uses a team of eight fund managers, told MarketWatch in an interview. Why the biggest-ever 'triple witching' options expiration could deliver a jolt to Friday's trading 'I'm at my wit's end': My niece paid off her husband's credit card but fell behind on her taxes. How can I help her? Israel-Iran clash delivers a fresh shock to investors. History suggests this is the move to make. How can I buy my niece a home in her name only — without alienating or upsetting her husband? My sister and her husband died within days of each other. Their banks won't let me access their safe-deposit boxes. What now? The fund has a 'long track record of protecting in periods of market volatility and market declines,' Patel said. The five-star Morningstar-rated fund AIVSX is ahead of the S&P 500 this year as well as over three- and five-year spans, according to Lipper data. The portfolio is filled with 'well-established U.S. companies with growth and income characteristics from a wide cross section of the economy,' said Patel. Some 80% of the fund is invested in dividend payers, a sweet spot that Patel says offers proof of capital discipline. As for the thus-far bumpy 2025? 'We're looking to find long-term winners within the investment universe, within the U.S., so this is just noise at the moment,' said Patel, who advises clients to 'stay invested, don't try to time the market, take a very long-term perspective.' The fund is overweight industrials, with an eye on commercial aviation and aircraft-engine manufacturer GE Aerospace GE, given how post-COVID air-travel recovery has driven demand for planes. 'Leading aircraft manufacturers cannot fill that gap, so there's a slowdown in manufacturing of these new aircrafts, and the demand for aircraft is so high, so there's a big gap,' she said. 'They're benefiting from strong aftermarket revenues, because the aircraft manufacturers are just not manufacturing the planes quick enough, and that adds resilience to GE's revenues, because those aftermarket revenues are recurring' — and, Patel said, resilient. Building-products companies like Carrier Global CARR are another industrials-sector area of interest for the fund. 'They incorporate technology within their [heating, ventilation and air conditioning] systems to make them energy-efficient, so they're going to benefit from the shift toward decarbonization, and also because about 40% of a building's greenhouse-gas emissions come from HVAC systems,' she said. As for another overweight, Abbott Laboratories ABT, one of the fund's oldest holdings, is a med-tech and diagnostic company 'exposed to the fastest-growing segments within healthcare, which is diabetes and heart valves,' said Patel, who adds that it Abbott hasn't cut its dividend in 50 years. 'So there's all this technology, and the markets are just not reflecting the full potential of innovation that's going on with the sector,' she said. The fund's biggest holding is Microsoft MSFT, which it has owned since 1993. She said she and her colleagues were impressed when they met CEO Satya Nadella after the leadership transition a decade ago, as they could see the 'direction of the growth potential of the company.' 'And today, if you look at the company, it's a leader in software, cloud computing and, actually, artificial intelligence through its partnership with OpenAI. It really has a strong competitive position, it's got a diversified revenue mix and it's got a recurring subscription model through its Office 365 products and its cloud computing products,' and has increased dividends for the last 20 years, she said. When it comes to AI, the fund is'very selective,' about exposure, but she says Microsoft offers a way in through its OpenAI link, while Carrier Global is a play on the materials that big AI data centers will need in their build-out. Need to Know: This five-star fund manager says even smart investors have been missing the greatest theme of our time Also read: OpenAI's Sam Altman thinks we may have already passed the point at which AI surpasses human intelligence A relative newcomer to the fund, Uber UBER was purchased in 2023, and Patel and company like it because it connects riders with drivers, but Patel said they're less keen on Tesla, which has a 'very capital-intensive' business. 'To break even and make a profit you need to utilize or increase the utilization rate of these driverless cars,' and the best way to do that is putting it in the biggest marketplace, such as Uber. Tesla TSLA is a 'very, very small position' in the fund — it's volatile and managers see better opportunities elsewhere, she said. See: A majority of the 10 most American-made cars are now EVs. That's a first. Patel said the market is broadening SPX, and many investors may not be seeing that. 'There are a number of sectors and industries that are doing much better than tech,' she said. 'I prepaid our mom's rent for a year': My sister is a millionaire and never helps our mother. How do I cut her out of her will? I'm 75 and have a reverse mortgage. Should I pay it off with my $200K savings — and live off Social Security instead? Why the stock market will be performing a high-wire act over the summer, according to UBS I'm 51, earn $129K and have $165K in my 401(k). Can I afford to retire when my husband, 59, draws Social Security at 62? Israel-Iran conflict poses three challenges for stocks that could slam market by up to 20%, warns RBC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging
The recent formation of the FIBRE Consortium, a collaboration involving Pfizer and other pharmaceutical partners, aims to pioneer advancements in fibrotic disease management. Alongside this, Pfizer's submission of a New Drug Application for vepdegestrant to treat breast cancer and significant progress in colorectal and prostate cancer therapies were key developments. Over the past month, Pfizer's stock saw a price increase of 4%. The company's performance appeared aligned with market trends amid geopolitical tensions and fluctuations in oil prices, indicating resilience within the broader mixed market conditions. These recent strategic initiatives have likely provided a positive foundation. We've identified 3 possible red flags with Pfizer and understanding the impact should be part of your investment process. Uncover 17 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The developments in Pfizer's strategic initiatives, specifically the formation of the FIBRE Consortium and the submission of the New Drug Application for vepdegestrant, could potentially enhance the company's revenue and earnings forecasts. These projects may strengthen Pfizer's position in the competitive pharmaceuticals landscape, especially as the company intensifies its focus on oncology. However, the ongoing threat of increased competition and reduced utilization of key drugs remain factors that may pressure revenue, possibly mitigating some of the positive impacts from the recent news. Over the past five years, Pfizer's total return, including share price and dividends, was a 1.05% decline, illustrating longer-term challenges despite short-term gains. On a one-year basis, the stock underperformed the US market, which achieved a 10.4% return, indicating some operational hurdles within the company. The recent strategic progress may offer potential relief if executed effectively. The stock's performance, with a recent monthly increase of 4%, places it in a unique position relative to the consensus analyst price target of US$29.24. The current share price of US$24.41 sits at a 22% discount to this target, hinting at potential upside according to more optimistic analysts. In contrast, some bearish analysts set a price target closer to US$24.57, suggesting that expectations are diverse. This disparity in views underscores the importance of closely monitoring how Pfizer's strategic developments influence its future performance and valuation. Jump into the full analysis health report here for a deeper understanding of Pfizer. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
